Celemics Inc is a Korea-based company mainly engaged in manufacturing products related to life science medicine. The Company mainly develops and sells target capture kit products. In addition, the Company is engaged in immune repertoire analysis solutions and next-generation sequencing solutions. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/26/17	14,290.00 ₩	0.00%	19,153
16/26/16	14,290.00 ₩	-2.66%	42,189
15/26/15	14,680.00 ₩	-3.86%	59,865
12/26/12	15,270.00 ₩	+0.66%	21,796
11/26/11	15,170.00 ₩	+0.93%	19,867

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 17/06/2026			5-day change	1st Jan Change
14,290.00 ^KRW	0.00%		-4.92%	+426.34%

29/05	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI
30/04	Celemics, Inc. announced that it has received KRW 8.292707441 billion in funding	CI

Market Cap	14TCr 9.24Cr 7.98Cr 7.33Cr 6.9Cr 13Cr 872.46Cr 13Cr 87Cr 34Cr 428.19Cr 35Cr 34Cr 1.48TCr	P/E 2024	2.19x	P/E 2025	-5.49x
Enterprise Value	13TCr 8.88Cr 7.66Cr 7.04Cr 6.63Cr 12Cr 837.93Cr 13Cr 83Cr 32Cr 411.24Cr 33Cr 33Cr 1.42TCr	EV / Sales 2024	2.56x	EV / Sales 2025	2.88x
Free-Float	84.27%	Yield 2024 *	-	Yield 2025	-

29/05	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI
30/04	Celemics, Inc. announced that it has received KRW 8.292707441 billion in funding	CI
28/04	Celemics, Inc. announced that it has received KRW 14.7 billion in funding	CI
31/03	Celemics, Inc. announced that it expects to receive KRW 11.5999945 billion in funding	CI
30/03	Celemics, Inc. announced that it expects to receive KRW 27 billion in funding	CI
13/03	Park Jong-gap completed the acquisition of an additional 5.27% stake in Celemics, Inc. from Kim Hyo-gi, Lee Yong-hoon.	CI
03/02	Celemics, Inc. announced that it expects to receive KRW 9.2927074 billion in funding	CI
03/02	Park Jong-gap agreed to acquire an additional 5.27% stake in Celemics, Inc. from Hyo-gi Kim, Yong-hoon Lee for KRW 2.6 billion.	CI
19/22/19	Celemics, Inc.(KOSDAQ:A331920) dropped from S&P Global BMI Index	CI
22/21/22	Celemics, Inc.(KOSDAQ:A331920) added to S&P Global BMI Index	CI
21/20/21	Celemics, Inc. has completed an IPO in the amount of KRW 26.4 billion.	CI
18/20/18	Celemics, Inc. has filed an IPO.	CI
08/15/08	Celemics Announces Expansion into North America with the Commencement of Celemics America, Inc	CI

1 week	-4.92%
Current month	-16.38%
1 month	+9.92%
3 months	+108.61%
6 months	+397.04%
Current year	+426.34%

Celemics, Inc. Share Price

Stocks

A331920

KR7331920009

Biotechnology & Medical Research

Valuation: Celemics, Inc.

Chart: Celemics, Inc.

Latest news : Celemics, Inc.

Press Releases: Celemics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Celemics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	14,000	16,190
1 month	12,500	18,240
Current year	2,580	19,840
1 year	2,535	19,840
3 years	2,535	19,840
5 years	2,535	22,350
10 years	2,535	39,400

Manager	Title	Age	Since
Yong-Hun Lee CEO	Chief Executive Officer	61	01/01/2017
Hyo-Gi Kim CEO	Chief Executive Officer	43	01/01/2013
Sang-Seok Lee PRN	Corporate Officer/Principal	45	01/01/2020

Director	Title	Age	Since
Hyo-Gi Kim BRD	Director/Board Member	43	01/01/2013
Yong-Hun Lee BRD	Director/Board Member	61	01/01/2017
Sang-Seok Lee BRD	Director/Board Member	45	01/01/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELEMICS, INC.	0.00%	-4.92%	+350.79%	+212.35%	9.24Cr
LONZA GROUP AG	-1.30%	-1.18%	-13.12%	-11.44%	4.34TCr
REVOLUTION MEDICINES, INC.	+0.76%	+9.42%	+303.09%	+540.82%	3.35TCr
IQVIA HOLDINGS INC.	-4.74%	-6.31%	+10.75%	-20.99%	2.85TCr
BEONE MEDICINES AG	-0.47%	-0.35%	+3.38%	+31.20%	2.92TCr
CELLTRION, INC.	+0.06%	+4.36%	+13.31%	+21.11%	2.53TCr
ASCENDIS PHARMA A/S	-0.02%	+10.18%	-	-	1.44TCr
MEDPACE HOLDINGS, INC.	-0.98%	-1.86%	+53.43%	+106.06%	1.31TCr
EUROFINS SCIENTIFIC SE	-1.25%	-4.04%	+2.05%	+2.90%	1.27TCr
IONIS PHARMACEUTICALS, INC.	+1.67%	+1.35%	+105.56%	+81.16%	1.23TCr
Average	-0.32%	+0.61%	+92.14%	+107.02%	2.12TCr
Weighted average by Cap.	-0.46%	+1.35%	+62.55%	+105.65%

	2024	2025
Net sales	671.9Cr 44.37L 38.28L 35.19L 33.12L 62.24L 42Cr 62.76L 4.17Cr 1.62Cr 21Cr 1.67Cr 1.63Cr 71Cr	576.76Cr 38.09L 32.86L 30.21L 28.43L 53.43L 36Cr 53.88L 3.58Cr 1.39Cr 18Cr 1.43Cr 1.4Cr 61Cr
Net income	1.23TCr 81L 69.88L 64.25L 60.47L 1.14Cr 76Cr 1.15Cr 7.61Cr 2.96Cr 38Cr 3.04Cr 2.98Cr 129.79Cr	-403.65Cr -26.65L -22.99L -21.14L -19.9L -37.39L -25Cr -37.71L -2.51Cr -97.54L -12Cr -1Cr -97.9L -43Cr
Net Debt	-954.81Cr -63.05L -54.39L -50.01L -47.07L -88.45L -60Cr -89.19L -5.93Cr -2.31Cr -29Cr -2.37Cr -2.32Cr -101.03Cr	-554.01Cr -36.58L -31.56L -29.02L -27.31L -51.32L -35Cr -51.75L -3.44Cr -1.34Cr -17Cr -1.37Cr -1.34Cr -59Cr